Logo image of BFRA

BIOFRONTERA AG (BFRA) Stock Fundamental Analysis

NASDAQ:BFRA - Nasdaq - ADR

2.67  -0.28 (-9.49%)

Fundamental Rating

1

BFRA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. BFRA may be in some trouble as it scores bad on both profitability and health. BFRA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BFRA has reported negative net income.
BFRA Yearly Net Income VS EBIT VS OCF VS FCFBFRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -10M -20M -30M

1.2 Ratios

Industry RankSector Rank
ROA -22.64%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BFRA Yearly ROA, ROE, ROICBFRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 200 -200 -400

1.3 Margins

Industry RankSector Rank
OM -42.23%
PM (TTM) -55.98%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BFRA Yearly Profit, Operating, Gross MarginsBFRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 -100 -200

More info and screens

1

2. Health

2.1 Basic Checks

BFRA has more shares outstanding than it did 1 year ago.
BFRA has a worse debt/assets ratio than last year.
BFRA Yearly Shares OutstandingBFRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 10M 20M 30M 40M
BFRA Yearly Total Debt VS Total AssetsBFRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 10M 20M 30M 40M 50M

2.2 Solvency

BFRA has an Altman-Z score of -2.09. This is a bad value and indicates that BFRA is not financially healthy and even has some risk of bankruptcy.
BFRA has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -2.09
ROIC/WACCN/A
WACCN/A
BFRA Yearly LT Debt VS Equity VS FCFBFRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 10M -10M 20M -20M -30M

2.3 Liquidity

BFRA has a Current Ratio of 1.26. This is a normal value and indicates that BFRA is financially healthy and should not expect problems in meeting its short term obligations.
BFRA has a Quick Ratio of 1.13. This is a normal value and indicates that BFRA is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.13
BFRA Yearly Current Assets VS Current LiabilitesBFRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.53% over the past year.
Looking at the last year, BFRA shows a very negative growth in Revenue. The Revenue has decreased by -15.27% in the last year.
BFRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 48.96% yearly.
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)-15.27%
Revenue growth 3Y36.15%
Revenue growth 5Y48.96%
Sales Q2Q%14.13%

3.2 Future

Based on estimates for the next years, BFRA will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.07% on average per year.
The Revenue is expected to grow by 6.84% on average over the next years.
EPS Next Y-137.77%
EPS Next 2Y-19.62%
EPS Next 3Y24.2%
EPS Next 5Y12.07%
Revenue Next Year-5.25%
Revenue Next 2Y8.35%
Revenue Next 3Y4.65%
Revenue Next 5Y6.84%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BFRA Yearly Revenue VS EstimatesBFRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
BFRA Yearly EPS VS EstimatesBFRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BFRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BFRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BFRA Price Earnings VS Forward Price EarningsBFRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -14.91
BFRA Per share dataBFRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as BFRA's earnings are expected to grow with 24.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.62%
EPS Next 3Y24.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BFRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOFRONTERA AG

NASDAQ:BFRA (3/4/2022, 8:19:41 PM)

2.67

-0.28 (-9.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap151.44M
Analysts80
Price Target14.22 (432.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.92
P/FCF N/A
P/OCF N/A
P/B 8.67
P/tB N/A
EV/EBITDA -14.91
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.54
BVpS0.31
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.64%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -42.23%
PM (TTM) -55.98%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.26
Quick Ratio 1.13
Altman-Z -2.09
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y-137.77%
EPS Next 2Y-19.62%
EPS Next 3Y24.2%
EPS Next 5Y12.07%
Revenue 1Y (TTM)-15.27%
Revenue growth 3Y36.15%
Revenue growth 5Y48.96%
Sales Q2Q%14.13%
Revenue Next Year-5.25%
Revenue Next 2Y8.35%
Revenue Next 3Y4.65%
Revenue Next 5Y6.84%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A